Dexcom
Corporate brand
UnclaimedA medical-technology company known for continuous glucose monitoring systems used in diabetes management.
Last updated August 27, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Dexcom is an American medical-technology company focused on continuous glucose monitoring (CGM), a category of devices that measures glucose levels through a small sensor worn on the body and communicates readings to a receiver, smartphone, smartwatch, or connected diabetes-management platform. Its systems are designed to provide repeated glucose readings and trend information throughout the day and night, helping users and healthcare professionals understand changing glucose levels and make more informed diabetes-management decisions. Founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, and Bret Megargel, Dexcom developed from a specialist medical-device company into one of the best-known dedicated CGM brands. The company received United States Food and Drug Administration clearance for its first commercial system, the Dexcom STS Continuous Glucose Monitoring System, in 2006. The three-day device established the company’s core proposition: giving people with diabetes frequent glucose information without requiring a separate finger-stick measurement for every reading. Dexcom followed it with the Seven system in 2007, which extended sensor wear to as much as seven days and improved accuracy. The company’s product development subsequently centered on longer-wear sensors, improved accuracy, wireless connectivity, remote data sharing, mobile applications, and integration with insulin-delivery systems. The Seven Plus arrived in 2009, while the G4 Platinum, introduced during the early 2010s, added a color receiver, extended transmission range, and improvements in low-glucose accuracy. A pediatric indication and the G4 Platinum with Share broadened the product’s use and enabled glucose data to be shared with designated followers through mobile applications. Dexcom’s G5 generation made Bluetooth connectivity a central part of the product experience. Following regulatory clearance in 2015 and 2016, users could send readings directly to compatible mobile devices, reducing reliance on a dedicated receiver. The G6, cleared in 2018, further developed the company’s connected CGM platform and became an important component in automated insulin-delivery partnerships. Dexcom has worked with insulin-pump and digital-health companies including Tandem Diabetes Care, Insulet, Companion Medical, Livongo, and Welldoc. These collaborations have connected CGM data with insulin pumps, smart pens, chronic-care platforms, and diabetes-management software. Dexcom’s G7, cleared by the FDA in December 2022, represents a newer generation of the company’s mainstream CGM platform. The company has also expanded beyond traditional prescription CGM through Stelo, an over-the-counter glucose monitor intended for eligible adults who do not use insulin. Time recognized Stelo as one of its best inventions of 2024. Dexcom has continued to position its brand around accuracy, ease of use, interoperability, data sharing, and making glucose information more accessible to people living with diabetes. Dexcom became a publicly traded company in 2005 and trades on Nasdaq under the symbol DXCM. It was added to the Nasdaq-100 in April 2020. Its global headquarters and research-and-development center are in San Diego, with manufacturing operations reported in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. The company operates internationally and has also established Dexcom Ventures, an investment arm focused on emerging CGM, analyte-sensing, medical-device, and medical-device cybersecurity technologies.
History
Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, and Bret Megargel to develop continuous glucose monitoring technology. The company’s central innovation was to make glucose information available repeatedly through a wearable sensor rather than relying exclusively on periodic finger-stick testing. Dexcom became publicly traded in 2005, establishing access to capital for regulatory development, manufacturing, and commercialization. The first major regulatory milestone came in 2006, when the FDA cleared the Dexcom STS Continuous Glucose Monitoring System. The STS used a three-day sensor and was designed to provide up to 288 glucose measurements over a 24-hour period. In 2007, Dexcom received approval for the Seven system. Its sensor could be used for up to seven days and improved accuracy compared with the earlier platform. During 2008, Dexcom announced development relationships with Insulet, Animas, and Edwards Lifesciences. These agreements reflected an early strategy of extending CGM beyond a standalone monitor into insulin delivery and hospital applications. Dexcom received FDA approval for the Seven Plus in February 2009, and the product obtained a CE mark later that year. The company continued to develop partnerships and platform integrations, although its development work for integration with Insulet was discontinued in 2013. In parallel, Dexcom expanded its own product family. The G4 Platinum received FDA and European approvals in 2012 for adults. It offered a color display, longer transmission range, and improved performance in detecting low glucose. The FDA expanded its use to people aged two to seventeen in 2014. In 2015, the G4 Platinum with Share enabled users to transmit data to designated followers through Dexcom’s Share and Follow applications. The G5 generation moved Dexcom further toward smartphone-based monitoring. In 2015, the FDA cleared the G5 as a standalone CGM and its transmitter incorporated Bluetooth connectivity, allowing readings to be sent directly to compatible mobile devices. The system also received European certification that year. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care in 2015 to support integration of the G5 and future G6 systems with Tandem insulin pumps. Dexcom also partnered with Google Life Sciences, later associated with Verily, on development work connected with the future G7 platform. The G6 received FDA approval in 2018 and became a key platform for connected diabetes care. Its data was integrated into insulin-delivery and digital-health ecosystems. Tandem’s Control-IQ technology, authorized in 2019, used Dexcom G6 readings with the t:slim X2 insulin pump to adjust insulin delivery in response to glucose levels. Dexcom also announced collaborations with Companion Medical, Livongo, Welldoc, and Insulet. These relationships connected CGM data with smart insulin pens, chronic-care services, digital coaching, and tubeless insulin delivery. A 2020 agreement with Insulet supported integration with the company’s Omnipod Horizon automated insulin-delivery system. Dexcom was added to the Nasdaq-100 in April 2020. In early 2021, it created Dexcom Ventures to invest in emerging CGM and analyte-monitoring technologies, as well as relevant medical-device software and cybersecurity. The company received FDA clearance for the G7 in December 2022. The G7 continued the company’s emphasis on compact wearable hardware, connected data, and simplified user experience. Dexcom later broadened its addressable market with Stelo, an over-the-counter glucose monitor for eligible adults who do not use insulin. In 2024, Stelo was recognized by Time as one of the year’s best inventions, and Dexcom announced a strategic data partnership with Oura. Dexcom’s global headquarters and research center remain in San Diego. Its reported manufacturing footprint includes Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland. The company’s history reflects the wider development of CGM from a specialist clinical tool into a connected consumer-facing and data-enabled platform used alongside insulin pumps, smart pens, mobile applications, and digital-care services.
- 2024
Stelo is recognized by Time
[1]Time names Dexcom Stelo among its best inventions of the year.
- 2022
G7 receives FDA approval
[1]The FDA clears the Dexcom G7 as a standalone CGM system.
- 2021
Dexcom Ventures is established
[1]The company launches a venture arm focused on glucose monitoring, analyte sensing, medical devices, and related software security.
- 2020
Dexcom joins the Nasdaq-100
[1]Dexcom becomes a component of the Nasdaq-100 index.
- 2018
G6 receives FDA approval
[1]The G6 becomes Dexcom’s next major connected CGM platform.
- 2016
G5 receives standalone FDA approval
[1]The G5 is approved for standalone use, with Bluetooth enabling direct transmission to compatible mobile devices.
- 2015
Dexcom expands connected-care partnerships
[1]Dexcom signs an integration agreement with Tandem Diabetes Care and announces development work with Google Life Sciences.
- 2012
G4 Platinum reaches the market
[1]The G4 Platinum receives FDA and European approvals for adult use and adds improvements in accuracy, transmission range, and display technology.
- 2009
Seven Plus receives regulatory clearance
[1]The FDA approves the Seven Plus, which later receives a CE mark.
- 2007
Dexcom Seven is approved
[1]The Seven system extends sensor use to as much as seven days and improves accuracy.
Products and positioning
A premium, technology-led CGM specialist emphasizing accuracy, real-time glucose visibility, connected care, interoperability, and user-friendly diabetes management.
Continuous glucose monitoring system · 2006
Dexcom STS
Dexcom’s first major commercial CGM system, cleared by the FDA in 2006. It used a three-day sensor and provided repeated glucose measurements during the day and night, establishing the product architecture that would define Dexcom’s later systems.
Continuous glucose monitoring system · 2007
Dexcom Seven
The second-generation Dexcom system, approved in 2007. It extended sensor wear from three to seven days and improved accuracy, making longer-duration monitoring a central part of Dexcom’s product proposition.
Continuous glucose monitoring system · 2009
Dexcom Seven Plus
An updated version of the Seven platform approved by the FDA in 2009. It continued Dexcom’s development of wearable glucose sensing before the company transitioned to the G-series products.
Continuous glucose monitoring system · 2012
Dexcom G4 Platinum
The G4 Platinum introduced a color receiver, longer transmission range, and improved low-glucose accuracy. Its approval was later expanded to pediatric users, and the G4 Platinum with Share added remote data sharing through Dexcom’s connected applications.
Connected continuous glucose monitoring system · 2015
Dexcom G5
The G5 brought integrated Bluetooth connectivity to Dexcom’s CGM platform. Its transmitter could send readings directly to compatible mobile devices, supporting use without the standalone receiver and enabling broader software and insulin-delivery integrations.
Connected continuous glucose monitoring system · 2018
Dexcom G6
Approved in 2018, the G6 is a connected CGM system that sends glucose readings and trend information to compatible receivers, phones, and digital-health platforms. It became a widely used data source for automated insulin-delivery collaborations, including Tandem’s Control-IQ ecosystem.
Continuous glucose monitoring system · 2022
Dexcom G7
The G7 is Dexcom’s next-generation mainstream CGM platform. FDA-cleared in December 2022, it continues the brand’s focus on wearable sensing, real-time readings, mobile connectivity, trend information, and integration with diabetes-management tools.
Extended-wear continuous glucose monitoring system
Dexcom G7 15-Day
An extended-wear G7 variant described as the most accurate currently approved CGM in the United States in the supplied reference material. It is intended to lengthen sensor use while retaining the G7 connected-monitoring experience.
Over-the-counter glucose monitor · 2024
Dexcom Stelo
Dexcom’s over-the-counter glucose-monitoring product for eligible adults who do not use insulin. Stelo extends the company’s glucose-sensing proposition beyond its traditional prescription CGM audience and was recognized by Time in 2024.
Brand decisions
2024
Expansion into over-the-counter glucose monitoringProduct launchBackground
Dexcom sought to reach eligible adults outside the traditional prescription CGM market.
Action taken
It introduced Stelo as an over-the-counter glucose monitor for adults who do not use insulin.
Aftermath
The product expanded Dexcom’s consumer-facing proposition and received recognition from Time as a notable invention of 2024.
2022
FDA clearance of Dexcom G7Product launchBackground
Dexcom needed to update its core CGM platform as the market moved toward smaller, simpler, and more connected wearable sensors.
Action taken
The FDA cleared the G7 for standalone use.
Aftermath
G7 became Dexcom’s next-generation flagship platform and continued the company’s emphasis on mobile connectivity and real-time glucose trends.
2021
Launch of Dexcom VenturesStrategyBackground
Dexcom identified opportunities in next-generation glucose monitoring, measurement of other analytes, medical devices, and device software security.
Action taken
The company created Dexcom Ventures as a venture-capital arm for investments in emerging technologies.
Aftermath
The initiative broadened Dexcom’s involvement in the wider sensing and connected-medical-device ecosystem.
2020
Global Insulet integration agreementStrategyBackground
Dexcom and Insulet pursued interoperability between CGM systems and Insulet’s tubeless insulin-delivery platform.
Action taken
The companies signed a non-exclusive global agreement covering current and future Dexcom CGM systems and Insulet’s Omnipod Horizon system.
Aftermath
The agreement was intended to support automated insulin delivery through CGM-informed dosing and smartphone-based control.
2015
Tandem insulin-pump integration agreementStrategyBackground
Dexcom sought to extend CGM data into insulin-delivery systems and connected diabetes care.
Action taken
It entered a non-exclusive agreement allowing Tandem Diabetes Care to integrate forthcoming Dexcom G5 and G6 systems with its insulin pumps.
Aftermath
The relationship supported later connected and automated insulin-delivery offerings, including Tandem Control-IQ using Dexcom G6 data.
Recent events
Reported
Dexcom launches corporate venture capital fund[3]
Dexcom said it was launching its first corporate venture capital fund to invest in companies working in sensing, data analytics, remote patient monitoring, population health and related technologies; the article says the fund was still in development.
Reported
Everside Health and Dexcom announce partnership to offer continuous glucose monitoring[4]
Healthstat, part of Everside Health, announced a partnership with Dexcom to offer Dexcom continuous glucose monitoring to its patients with Type 2 diabetes.
Reported
Dexcom appoints Karen Dahut to its board[5]
DexCom announced that Karen Dahut was appointed to its Board of Directors, effective immediately.
Reported
Insulet and Dexcom announce Omnipod Horizon integration agreement[6]
Insulet and Dexcom announced a global commercialization agreement to combine Dexcom continuous glucose monitoring technology with Insulet’s Omnipod Horizon automated insulin delivery system. The system is intended to use Dexcom G6 and next-generation G7 sensor values, once available.
Reported
Dexcom and Tandem partner to distribute integrated diabetes system in four European markets[7]
Dexcom partnered with Tandem Diabetes Care in the UK, Sweden, Italy and Spain to distribute the Dexcom G6 CGM System integrated with Tandem's t:slim X2 insulin pump.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/dexcom · Editorial policy · How profiles are compiled